WC-2

WC-2 (11-point 3-fold serial dilutions; 30 min preincubation, 30 min reaction) inhibits full-length WRN helicase ATPase activity (100 μM ATP) with an IC₅₀ of 250 nM^[1].
WC-2 inhibits full-length WRN helicase activity with an apparent kinet/K_i value of 1593 M^-1s^-1[1].
WC-2 (10-point 3-fold serial dilutions; 48 h) induces p21 expression in HCT116 MSI-H colon carcinoma cells with an unbound AC₅₀ of 31 nM^[1].
WC-2 (10-point 3-fold serial dilutions; 7 days) selectively inhibits viability of HCT116 MSI-H colon carcinoma cells with an unbound IC₅₀ of 3 nM, while sparing HT29 MSS colon carcinoma cells^[1].
WC-2 (1 μM; up to 1185 min) shows very low reactivity with GSH in pH 7.4 buffer, with a half-life of >2400 min^[1].
WC-2 (5 μM; up to 240 min) is highly stable in human plasma, with a half-life of >480 min^[1].
WC-2 (5 μM; up to 240 min) is highly stable in human whole blood, with a half-life of >480 min^[1].
WC-2 (10 μM) exhibits favorable cell penetration in the Caco-2 monolayer system, with an A to B P_app of 3.0 × 10^-6 cm/s and an efflux ratio of 1^[1].
WC-2 does not significantly inhibit hERG channels, with an IC₅₀ > 10 μM^[1].
WC-2 has excellent metabolic stability in human and rat liver microsomes, with intrinsic clearance < 10 μL/min/mg (human) and < 18 μL/min/mg (rat)^[1].
WC-2 has favorable metabolic stability in human, rat, and dog hepatocytes, with intrinsic clearance values of 6.3, 18.9, and 25.0 μL/min/10⁶ cells respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.